AbSci AI
AbSci / absci.com
Generative AI platform for designing antibodies and protein therapeutics, using deep learning to generate novel drug candidates with desired properties rather than screening large molecular libraries.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
No
Open source
No
Platforms
2
Advertisement
What is AbSci AI?
AbSci is a synthetic biology and AI company focused on using generative AI to design antibody and protein therapeutics. Rather than discovering drugs by screening vast libraries of existing molecules, AbSci's AI generates novel molecules with specified binding and functional properties — a fundamental shift from testing existing molecules toward designing new ones from scratch.
The Zero-Shot Protein Design platform uses generative AI trained on protein structure and function data to design novel antibodies with specified binding characteristics — telling the AI the target protein and desired binding affinity, and the AI generates candidate antibody sequences predicted to have those properties.
Drug-target interaction AI predicts how candidate molecules will interact with target proteins, estimating binding affinity and specificity without requiring synthesis and physical testing of each candidate. This computational prediction dramatically reduces the experimental cycle by screening in silico before committing to synthesis.
Cell line engineering AI optimises the biological production systems for manufacturing designed therapeutics — critical for scaling drug candidates from laboratory design to pharmaceutical manufacturing.
AbSci's published research has demonstrated zero-shot antibody design — generating functional antibody candidates for targets without prior experimental data for that specific target. Published in peer-reviewed journals including Nature, this research validates the scientific approach and positions AbSci in the generative AI for drug discovery field alongside Recursion and Insilico Medicine.
AbSci's business model combines pharmaceutical partnerships (licensing AI-designed drug candidates to pharma companies) with platform technology licensing to companies wanting AI-assisted drug design capabilities.
How AbSci AI works
AbSci AI runs as deep learning model software built around data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating AbSci AI.
Zero-shot antibody design
Generative AI creates novel antibody sequences for protein targets without prior experimental data for that target, designing functional candidates from learned protein structure principles.
Drug-target interaction prediction
AI predicts binding affinity and specificity of candidate molecules computationally before synthesis, screening candidates in silico to prioritise the most promising for experimental validation.
Pharmaceutical partnership model
Revenue from licensing AI-designed drug candidates and platform technology to pharmaceutical companies rather than advancing drugs through clinical trials independently.
Best use cases
Who should use it
Pros
- Published zero-shot antibody design research in peer-reviewed journals validates the generative AI approach
- Publicly traded company provides financial transparency and stability versus private biotech competitors
- Generative design approach creates novel molecules rather than optimising existing ones — different innovation mode
- Pharmaceutical partnership model provides revenue without requiring AbSci to advance drugs independently through clinical trials
Cons
- Very early commercial stage — generative AI drug discovery has not yet produced approved drugs
- Pharmaceutical partnership revenue is lumpy and dependent on partner decisions and clinical outcomes
- Competing with well-funded competitors including Recursion, Insilico Medicine, and Isomorphic Labs
Advertisement
Is it worth the price?
Pharmaceutical partnership model. No public pricing. Publicly traded company (ABSI). Research collaborations.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like AbSci AI
Recursion (covered, rank 372) focuses on high-throughput biological screening AI. Insilico Medicine (covered) focuses on generative small molecule drug discovery. Isomorphic Labs (DeepMind) applies protein AI to drug design. Genentech AI is a major pharma in-house AI drug discovery operation.
AbSci AI vs Insilico Medicine
A side-by-side look at the closest alternative in this category.
AbSci AI
AbSci
Insilico Medicine
Insilico Medicine
Pharmaceutical partnership model. No public pricing. Publicly traded company (ABSI). Research collaborations.
Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.
Research data handling agreements. GDPR compliant. Enterprise pharmaceutical partnership data handling agreements.
Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.
Biological research data and drug candidate designs handled under pharmaceutical partnership data handling agreements and applicable research ethics frameworks.
Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.
- Published zero-shot antibody design research in peer-reviewed journals validates the generative AI approach
- Publicly traded company provides financial transparency and stability versus private biotech competitors
- Generative design approach creates novel molecules rather than optimising existing ones — different innovation mode
- Pharmaceutical partnership model provides revenue without requiring AbSci to advance drugs independently through clinical trials
- INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
- Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
- First company to advance a fully AI-designed drug candidate to clinical trials
- NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment
- Very early commercial stage — generative AI drug discovery has not yet produced approved drugs
- Pharmaceutical partnership revenue is lumpy and dependent on partner decisions and clinical outcomes
- Competing with well-funded competitors including Recursion, Insilico Medicine, and Isomorphic Labs
- Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
- Clinical success probability remains uncertain — most drug candidates fail in clinical trials
- Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
AbSci
Platforms
Web, API
Deployment
SaaS, Research partnership
Integrations
Pharmaceutical research systems, API
Team Collaboration
No
Launch Year
2023
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
Research data handling agreements. GDPR compliant. Enterprise pharmaceutical partnership data handling agreements.
Biological research data and drug candidate designs handled under pharmaceutical partnership data handling agreements and applicable research ethics frameworks.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate AbSci AI and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about AbSci AI
Editorial Verdict
Should you use AbSci AI?
AbSci is a leading generative AI antibody design company for pharmaceutical partnerships, with published research validating zero-shot antibody generation and a publicly traded company structure providing transparency.
Last verified July 24, 2026.